Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.57 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | HTT | P42858 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678921 | 0.91 | MAPT (0.70) | MAPTPLA2G1BATG4BMEN1KMT2A | |
| SCHEMBL7249161 | 0.90 | MAPT (0.58) | MAPTPLA2G1BATG4BMEN1KMT2A | |
| SCHEMBL4675197 | 0.85 | POLB (0.51) | MAPTMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL4674103 | 0.82 | NPC1 (0.55) | MAPTALDH1A1GCGRMAPK1LMNA | |
| SCHEMBL4678420 | 0.81 | POLB (0.47) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL4677063 | 0.80 | POLB (0.47) | MAPTMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL4674283 | 0.80 | POLB (0.69) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL19246210 | 0.78 | MAPT (0.68) | MAPTPLA2G1BATG4BMEN1KMT2A | |
| SCHEMBL18757839 | 0.77 | ALDH1A1 (0.56) | MAPTPLA2G1BATG4BMEN1KMT2A | |
| SCHEMBL2449511 | 0.77 | SMN1; SMN2 (0.50) | MAPTHTTALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | claimed |
| EP-1392639-A4 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2006-01-25 | — | — | EP | claimed |
| EP-1392639-A1 | PYRUVATE DERIVATIVES | Galileo Laboratories, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2002090314-A1 | PYRUVATE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1392639-A4 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6916850-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6900218-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1392639-A1 | PYRUVATE DERIVATIVES | Galileo Laboratories, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | disclosed |
| US-20030013657-A1 | Pyruvate derivatives | MONSANTO TECHNOLOGY, LLC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002090314-A1 | PYRUVATE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013847-A1 | Cytoprotective agents | PC, PDK1, PDK2 | MAPT 1203/4885PLA2G1B 1749/4885ATG4B 1826/4885 |
| US-20030013657-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | MAPT 851/4885PLA2G1B 2624/4885ATG4B 2876/4885 |
| US-20030013846-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | MAPT 851/4885PLA2G1B 2624/4885ATG4B 2876/4885 |
| US-20030013656-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | MAPT 851/4885PLA2G1B 2624/4885ATG4B 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.